

01/02/2021

# How to consider the XETA in the assessment strategy of the ECHA/EFSA ED Guidance

**Maria Arena<sup>1</sup>, Sander Van der Linden<sup>2</sup>, Aude  
Kienzler<sup>1</sup>**


**<sup>1</sup>EFSA, PREV Unit**

**<sup>2</sup>ECHA, Biocidal Active Substance Unit**

# Webinar guide for attendees

- This webinar is being recorded.
- The webinar is in English and questions should be submitted in English through the platform (see hereunder).
- You are automatically connected to the audio broadcast. One-way audio (listen only mode).

Presentation window





**Q&A box:**  
For any questions related to the topic or unexpected IT issues

- Background
- General description and limitations of the XETA
- How to consider the XETA in the assessment strategy of the ECHA/EFSA Guidance: Case 1
- How to consider the XETA in the assessment strategy of the ECHA/EFSA Guidance: Case 2
- Q&A and Conclusion

- OECD TG published in 2019
- Annex to the Guidance drafted mid-2020
- Targeted consultation with EFSA MSs and ECHA EDEG and BPC Environment Working Group in Oct-Nov 2020
- Webinar with stakeholders today
- Finalisation of the Annex and publication

# Xenopus Eleutheroembryonic Thyroid Assay






The TH/bZIP gene codes for a transcription factor associated with amphibian metamorphosis, a process controlled by THs

Thyroidal MoA covered by XETA		
T-MoA	Substances tested for validation	
Modulators of TH clearance including UDP-glucuronosyltransferase modulators	Phenobarbital	✓
Modulators of TH metabolism, including deiodinase inhibitors	Iopanoic acid	✓
Thyroid receptor agonist	T4, TRIAC	✓
Thyroid receptor antagonist	NH3	✓
Interference with THs synthesis	-	✗
Interference with TH transport via interaction with TH plasma binding proteins or Inhibition of TH transmembrane transporters	-	✗


# MoA covered by XETA





# XETA in the assessment strategy

The ECHA/EFSA Guidance (2018) recommends to first conclude on the ED properties with regard to humans and in parallel, using the same data package, on mammals as non-target organisms. Only if the criteria are not met for mammals as non-target organisms, the assessment should proceed considering other taxonomic groups and in particular fish and amphibians.




## XETA is considered suitable for:

**Case 1:** ED criteria not met for humans and wild mammals

**Case 2:** ED criteria met for humans but not for mammals as NTOs

# Case 1



A XETA is considered a suitable test when:

- ✓ No adversity was observed in mammals based on a complete dataset
- ✓ Although some effects in T-mediated parameters were observed, a T-mediated MoA was excluded


**It is important when deciding on a XETA vs an AMA that all the available information, including Level 1, are considered.**

## XETA is considered suitable for:

**Case 1:** ED criteria not met for humans and wild mammals

**Case 2:** ED criteria met for humans but not for mammals as NTOs

# Case 2



T-mediated adversity identified in mammals:

- ❖ It is considered to be caused by a T-mediated MoA

**AND**

- ❖ It is not relevant for wild mammal populations

**Further data are needed on NTOs other than mammals**

A XETA might be suitable when the identified MoA is not:

- ❖ TPO inhibition
- ❖ NIS inhibition
- ❖ Modulators of TH transport via interaction with TH plasma binding proteins
- ❖ Inhibition of TH transmembrane transporters

**Note:** if the XETA is positive a MoA analysis should be performed and further data needed on adversity. Therefore, performance of a level 4 study, instead of a level 3, would address both endocrine activity and adversity.



1. In both cases 1 and 2, if the XETA is negative, the endocrine activity for the T-modality for non-target organisms other than mammals is considered sufficiently investigated and the ED criteria are not met.
2. A negative XETA alone may not be sufficient to conclude on the ED properties of a substance. The conclusion has always to be reached based on WoE
3. If the XETA is positive , according to Figure 1 of the ECHA/EFSA Guidance (ECHA/EFSA, 2018), a Mode of Action Analysis should be performed and further testing might be needed, i.e. a test according to OECD TG 241.

- ❑ Francesco Amoretti
- ❑ Anna Campanini
- ❑ Carla Dall'Aglio
- ❑ Alberto Goldoni





# Thank you for attending our webinar!

In case we did not manage to answer all your questions, please feel free to re-submit them via e-mail

[pesticides.peerreview@efsa.europa.eu](mailto:pesticides.peerreview@efsa.europa.eu)

The recording of today's webinar will be available on the EFSA website in few days

Please take few minutes to fill out the evaluation form that you will receive shortly in your inbox. Your feedback is essential to improve our future events



## **Subscribe to**

[www.efsa.europa.eu/en/news/newsletters](http://www.efsa.europa.eu/en/news/newsletters)  
[www.efsa.europa.eu/en/rss](http://www.efsa.europa.eu/en/rss)



## **Engage with careers**



## **Follow us on Twitter**

@efsa\_eu  
@plants\_efsa  
@methods\_efsa